Marker Therapeutics Inc. has announced a collaboration with Cellipont Bioservices to advance the cGMP manufacturing of their lead Multi-Antigen Recognizing $(MAR)$-T cell therapy, MT-601, for patients with lymphoma. This partnership aims to support the scale-up and production of MT-601 for the ongoing Phase 1 APOLLO study, which is investigating the therapy in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy or for whom such therapy is not an option. The APOLLO study has already reported favorable safety results and objective responses in 78% of participants, with a 44.4% complete response rate observed in some patients as early as four weeks post-infusion. The collaboration is designed to accelerate clinical supply and prepare for potential pivotal trials and commercial readiness.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Marker Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-060092), on June 17, 2025, and is solely responsible for the information contained therein.
Comments